Translational Oncology
Overview
Translational Oncology is a peer-reviewed journal that focuses on bridging the gap between basic science and clinical research in the field of oncology. It publishes cutting-edge studies that aim to translate laboratory discoveries into practical applications for cancer prevention, diagnosis, and treatment. The journal serves as a platform for researchers, clinicians, and policymakers to share their findings and insights, ultimately advancing the understanding and management of cancer.
Details
Details
Abbr.
Transl Oncol
Start
2007
End
Continuing
e-ISSN
1936-5233
Country
United States
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 4950
72
SJR / Ranks: 2603
1263
CiteScore / Ranks: 2750
7.20
JIF / Ranks: 1573
5.0
Recent Articles
1.
Kohl S, Subtil F, Climenti V, Anees H, Parplys A, Engenhart-Cabillic R, et al.
Transl Oncol
. 2025 Mar;
55:102359.
PMID: 40088750
Objectives: Human papilloma virus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) cells are highly radiosensitive resulting from an elevated number of DNA double-strand breaks (DSB) remaining after irradiation. Partially...
2.
Xu P, Zhang Q, Zhai J, Chen P, Deng X, Miao L, et al.
Transl Oncol
. 2025 Mar;
55:102344.
PMID: 40088749
Introduction: Aberrant expression of APOA1 has been reported in various cancers. However, a comprehensive investigation into its role in cancer is currently lacking. Methods: Online websites and databases such as...
3.
Kabeli R, Boursi B, Zilberberg A, Efroni S
Transl Oncol
. 2025 Mar;
55:102358.
PMID: 40088748
This study investigates the T-cell receptor (TCR) repertoires in colorectal cancer (CRC) patients by analyzing three distinct datasets: one bulk sequencing dataset of 205 patients with various tumor stages, all...
4.
Rueff J, Conde J, Castro G
Transl Oncol
. 2025 Mar;
55:102356.
PMID: 40086325
The study of cancer, its initiation, and its mechanisms of progression has been a focal point in science for more than a century. Despite controversies among scientists, there is a...
5.
Wang H, Qiu B, Li X, Ying Y, Wang Y, Chen H, et al.
Transl Oncol
. 2025 Mar;
55:102347.
PMID: 40086324
Patients with liver metastatic colorectal cancer (mCRC) have a poor prognosis and are the leading cause of death in colorectal cancer (CRC) patients, but the mechanisms associated with CRC metastasis...
6.
Zhang X, Li P, Ji L, Zhang Y, Zhang Z, Guo Y, et al.
Transl Oncol
. 2025 Mar;
54:102349.
PMID: 40073802
Background: Mesenchymal stem cells (MSCs), due to their tumor-targeting homing properties, are present in the tumor microenvironment (TME) and influence the biological behaviors of tumors. The purpose of this paper...
7.
Chai Y, Zhang J, Shao W, Zhang Z
Transl Oncol
. 2025 Mar;
54:102341.
PMID: 40068384
Background: Head and neck squamous cell carcinoma (HNSCC) is a prevalent malignancy often diagnosed in advanced stages. Despite advancements in therapy, it retains a high mortality rate and significant recurrence...
8.
Liu Y, Xue N, Liu Y, Mei J, Cai Y, Wang Z, et al.
Transl Oncol
. 2025 Mar;
54:102343.
PMID: 40068383
Background: The tumor stroma has been reported to be associated with worse prognosis in several solid tumors, but its prognostic value in breast cancer (BRCA) is still undefined. Methods: In...
9.
Chou M, Yang M
Transl Oncol
. 2025 Mar;
54:102353.
PMID: 40058234
The emergence of molecularly targeted therapies and immunotherapies has revolutionized cancer treatment, yet the optimal sequencing of these modalities remains debated. While targeted therapies often induce initial immunostimulatory effects, the...
10.
Ding R, Li Y, Zhang Y, Li X, Song Y, Gu X, et al.
Transl Oncol
. 2025 Mar;
54:102338.
PMID: 40058233
Gastric cancer is one of the malignant tumors with the highest morbidity and mortality rates worldwide. Yet, there is a lack of diagnostic markers with high sensitivity in the clinic....